Spine and Non-spine Bone Metastases - Current Controversies and Future Direction.

Bone metastases bone-modifying agents bone-targeted radionuclides palliative radiotherapy surgery

Journal

Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902

Informations de publication

Date de publication:
11 2020
Historique:
received: 08 04 2020
revised: 21 05 2020
accepted: 10 07 2020
pubmed: 5 8 2020
medline: 29 5 2021
entrez: 5 8 2020
Statut: ppublish

Résumé

Bone is a common site of metastases in advanced cancers. The main symptom is pain, which increases morbidity and reduces quality of life. The treatment of bone metastases needs a multidisciplinary approach, with the main aim of relieving pain and improving quality of life. Apart from systemic anticancer therapy (hormonal therapy, chemotherapy or immunotherapy), there are several therapeutic options available to achieve palliation, including analgesics, surgery, local radiotherapy, bone-seeking radioisotopes and bone-modifying agents. Long-term use of non-steroidal analgesics and opiates is associated with significant side-effects, and tachyphylaxis. Radiotherapy is effective mainly in localised disease sites. Bone-targeting radionuclides are useful in patients with multiple metastatic lesions. Bone-modifying agents are beneficial in reducing skeletal-related events. This overview focuses on the role of surgery, including minimally invasive treatments, conventional radiotherapy in spinal and non-spinal bone metastases, bone-targeting radionuclides and bone-modifying agents in achieving palliation. We present the clinical data and their associated toxicity. Recent advances are also discussed.

Identifiants

pubmed: 32747153
pii: S0936-6555(20)30292-2
doi: 10.1016/j.clon.2020.07.010
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

728-744

Informations de copyright

Copyright © 2020 The Royal College of Radiologists. All rights reserved.

Auteurs

A Challapalli (A)

Department of Clinical Oncology, Bristol Cancer Institute, Bristol, UK. Electronic address: amarnath.challapalli@uhbw.nhs.uk.

S Aziz (S)

Department of Orthopaedics, University Hospitals of Leicester, Leicester, UK.

V Khoo (V)

Department of Clinical Oncology, Royal Marsden Hospital, London, UK.

A Kumar (A)

Department of Orthopaedics, Manchester University Hospitals, Manchester, UK.

R Olson (R)

Department of Radiation Oncology, BC Cancer Centre for the North, British Columbia, Canada.

R U Ashford (RU)

Department of Orthopaedics, University Hospitals of Leicester, Leicester, UK; Leicester Cancer Research Centre, University of Leicester, Leicester, UK.

O A Gabbar (OA)

Department of Orthopaedics, University Hospitals of Leicester, Leicester, UK.

B Rai (B)

Department of Radiotherapy & Oncology, PGIMER, Chandigarh, India.

A Bahl (A)

Department of Clinical Oncology, Bristol Cancer Institute, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH